Alphyn Announces First Patient Dosed in CLEAR-AD1 Global Phase 2b Clinical Trial Program of Zabalafin Hydrogel for Atopic Dermatitis
Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that the first patient has been dosed in its CLEAR-AD1 Phase 2b clinical trial of Zabalafin Hydrogel in Australia. The trial will evaluate...